Overview
- Insulet reported Q1 revenue of $762 million, up 30% in constant currency, and raised 2026 growth guidance to 21%–23%.
- International Omnipod revenue grew about 45%, outpacing 28% growth in the U.S., with record new customer starts in the U.K.
- Adjusted operating margin expanded by 110 basis points to 17.5%, while excess and obsolete pod costs cut gross margin by more than 150 basis points.
- Management flagged near-term pressure from a $10 million distributor timing boost reversing in Q2, $12 million tied to a March device correction, and higher shipping and raw-material costs linked to Middle East conflict.
- Near-term plans include Omnipod 5 compatibility with Libre 3 Plus, a new dosing algorithm this year, Omnipod 6 in 2027, and a fully closed-loop Type 2 system targeted for 2028, which could open access for roughly 450,000 current Libre users.